Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -63.8%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $6M | — | — | — | — | — |
| Enterprise Value | $-12149559 | — | — | — | — | — |
| P/E Ratio → | -0.37 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 0.35 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 100.0% | 96.0% |
| Operating Margin | — | — | 22.3% | -75.3% | -185.5% | -173.7% |
| Net Profit Margin | — | — | 27.2% | -65.2% | -133.8% | -118.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -63.8% | -63.8% | 61.7% | -82.7% | -106.9% | -83.5% |
| ROA | -53.5% | -53.5% | 21.9% | -21.3% | -30.9% | -23.7% |
| ROIC | -92.7% | -92.7% | 43.8% | -82.6% | -118.5% | -92.1% |
| ROCE | -69.9% | -69.9% | 21.8% | -29.0% | -49.1% | -39.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.52 | 0.18 | 0.17 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.06 | -0.11 | -0.17 | -0.12 | -0.00 |
| Net Debt / EBITDA | — | — | -0.25 | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — |
Net cash position: cash ($18M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 13.50 | 13.50 | 4.88 | 5.29 | 6.84 | 8.15 |
| Quick Ratio | 13.50 | 13.50 | 4.88 | 5.29 | 6.84 | 8.15 |
| Cash Ratio | 13.30 | 13.30 | 4.59 | 4.95 | 6.27 | 7.59 |
| Asset Turnover | — | — | 1.58 | 0.40 | 0.23 | 0.20 |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 0.64 | 90.08 | 79.53 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | 65.6% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $7M | $7M | $7M | $6M | $6M |
Existential capital depletion risk
According to recent financial data, LITS trades at a price-to-book ratio of 0.35, a valuation level that suggests the market is pricing the entity as a distressed shell rather than a functional asset manager with future growth prospects.
The P/B ratio of 0.35 indicates that the market is discounting the company's assets significantly, likely due to the high uncertainty surrounding the transition from oncology to digital asset management. This valuation implies that investors are skeptical of the firm's ability to deploy its remaining capital effectively, viewing the current book value as potentially overstated by legacy liabilities.
As reported in quarterly filings, the company's ROIC has remained consistently negative, reaching -3.4% in 2026Q3, which highlights a fundamental inability to generate positive returns on the capital currently deployed within the business.
The negative ROIC trend over the last ten quarters confirms that the firm is destroying value rather than compounding it. This decay is driven by the lack of operational revenue combined with ongoing overhead, suggesting that the current capital allocation strategy is failing to provide a viable path toward profitability.
Based on the 2026Q3 balance sheet, the company maintains a current ratio of 11.53, a figure that appears deceptively strong but primarily reflects the rapid liquidation of legacy assets rather than a healthy, self-sustaining operational liquidity position.
While a current ratio of 11.53 suggests high short-term solvency, it is misleading in the context of a firm with zero revenue and ongoing cash burn. Investors should monitor this metric closely, as the rapid consumption of cash reserves will likely cause this ratio to deteriorate quickly if the pivot to crypto-asset management does not yield immediate results.
The current ratio is the most commonly misapplied metric for LITS, as it obscures the reality that the company's high liquidity is a temporary byproduct of asset liquidation rather than a sign of operational strength or financial health.
Using the current ratio to assess LITS is fundamentally flawed because it treats all current assets as equally available for operations, ignoring the potential for significant tail liabilities from the legacy pharmaceutical business. A more appropriate metric would be a 'burn-adjusted' cash runway, which would better reflect the company's actual survival timeline in the absence of revenue.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LITS stock.
Lite Strategy, Inc.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Lite Strategy, Inc.'s return on equity (ROE) is -63.8%. The historical average is -55.0%.
Based on historical data, Lite Strategy, Inc. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.